An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
Status:
Completed
Trial end date:
2019-06-24
Target enrollment:
Participant gender:
Summary
T-1101 is a novel anti-cancer agent being developed by Taivex Therapeutics Corporation, and
is being studied in a phase I dose escalation trial, protocol TAI-001. That trial's primary
aim is to study the safety and tolerability of T-1101 (Tosylate) in subjects with advanced
refractory solid tumors, and provides for a maximum of 2 cycles of treatment. At the end of 2
cycles of treatment, it is likely that some patients will be continuing to receive clinical
benefit from T-1101 (Tosylate). The intention of this program is to enable these patients to
continue to receive T-1101 (Tosylate) at the discretion of the principal investigators and
Taivex Therapeutics Corporation.